What is the debt of Neovacs this year?
Neovacs has a debt level of -0.24 EUR this year.
Neovacs Debt 2024
Neovacs Debt
-0.24 EUR
Ticker
ALNEV.PA
ISIN
FR0004032746
WKN
A1CVKR
In 2024, Neovacs's total debt was -0.24 EUR, a -120.37% change from the 1.16 EUR total debt recorded in the previous year.
Neovacs Aktienanalyse
What does Neovacs do?
Neovacs SA is a French biotechnology company specializing in the development of immunotherapies for the treatment of autoimmune diseases and cancer. It was founded in 1993 by Pierre Vandepapeliere and is headquartered in Paris. The company has a history of groundbreaking discoveries and continuous innovation. Its business model is based on the combination of cutting-edge research and the development of customized therapies for the treatment of autoimmune diseases and cancer. Neovacs SA identifies specific proteins that trigger an immune response against the body's own cells and tissues, and develops Kinoid vaccines to neutralize these proteins and stop the autoimmune reaction. It is also specialized in the development of immunotherapies for the treatment of cancer. The main divisions of Neovacs SA are clinical development, regulatory affairs, and the manufacturing of Kinoid vaccines. It has achieved an impressive track record in the clinical development of Kinoid vaccines and collaborates with leading universities, hospitals, and research institutions to support its research and development activities. The company currently offers a range of different Kinoid vaccines for the treatment of autoimmune diseases, including a product for the treatment of lupus, a product for the treatment of rheumatoid arthritis, and a product for the treatment of chronic hepatitis B. All of these products are currently in Phase 2 development. Another important product being developed by Neovacs SA is an immunotherapeutic for the treatment of cancer. Known as TNF-Kinoid, the product aims to enhance the body's immune defense against cancer cells and inhibit tumor growth. It has shown promising results in Phase 1 clinical development and is currently in Phase 2 development. Neovacs SA is a strong and growing company in a rapidly evolving sector of biotechnology. It has an impressive track record in the clinical development of immunotherapies for the treatment of autoimmune diseases and cancer, and is well-positioned to continue making significant contributions to healthcare. Neovacs ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Neovacs's Debt Structure
Neovacs's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Neovacs's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Neovacs’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Neovacs’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Neovacs stock
What was the debt of Neovacs compared to the previous year?
The debt of Neovacs has increased by -120.37% compared to the previous year dropped.
What are the consequences of high debt for investors in Neovacs?
High debt can pose a risk for investors of Neovacs, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Neovacs?
Low debt means that Neovacs has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Neovacs affect the company?
An increase in debt of Neovacs can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Neovacs affect the company?
A reduction in debt of Neovacs can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Neovacs?
Some factors that can influence the debt of Neovacs include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Neovacs so important for investors?
The debts of Neovacs are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Neovacs take to change the debt?
To change the debt, Neovacs can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Neovacs pay?
Over the past 12 months, Neovacs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neovacs is expected to pay a dividend of 0 EUR.
What is the dividend yield of Neovacs?
The current dividend yield of Neovacs is .
When does Neovacs pay dividends?
Neovacs pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neovacs?
Neovacs paid dividends every year for the past 0 years.
What is the dividend of Neovacs?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neovacs located?
Neovacs is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neovacs kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neovacs from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Neovacs pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Neovacs in the year 2023?
In the year 2023, Neovacs distributed 0 EUR as dividends.
In which currency does Neovacs pay out the dividend?
The dividends of Neovacs are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neovacs
Our stock analysis for Neovacs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
